Radiolabeled MGLL Occupancy Probe for CNS Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack non-invasive quantitative techniques for evaluating monoacylglycerol lipase (MGLL) expression and enzyme occupancy in the central nervous system (CNS), which is crucial for developing therapeutic drugs targeting CNS disorders.
Innovation Solution
Development of radiolabeled MGLL occupancy probes containing positron emission tomography (PET) tracer radionuclides like 18F, 15O, or 13N, which form covalent adducts with the active-site serine in MGLL, enabling imaging and occupancy studies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radiolabeled MGLL occupancy probes with PET tracer radionuclides are developed, then non-invasive assessment of MGLL enzyme occupancy is enabled, but the complexity of the imaging system increases
Solution Approach 1:
The patent introduces radiolabeled MGLL occupancy probes as intermediary agents that bind to MGLL enzymes in the CNS. These probes contain PET tracer radionuclides (18F, 15O, or 13N) that serve as mediators between the target enzyme and the imaging system, enabling non-invasive detection of enzyme occupancy without direct observation of the enzyme itself
Solution Approach 2:
The patent replaces invasive mechanical sampling methods with a non-invasive imaging approach. Instead of physically extracting tissue samples to measure MGLL occupancy, the invention uses PET imaging technology to detect radiolabeled probes in vivo, substituting mechanical intervention with electromagnetic detection
2Reliability
If radiolabeled probes forming covalent adducts with active-site serine are used, then target engagement specificity is improved, but the chemical complexity of the probe increases
Solution Approach 1:
The patent applies local quality by concentrating the complexity only where needed - the radiolabeled probe contains sophisticated structures (Formula I with specific substituents) only at the binding interface with MGLL's active-site serine, while the rest of the molecular structure remains relatively simple to facilitate synthesis and imaging
Solution Approach 2:
The patent changes the chemical bonding parameter from reversible to covalent interaction. The radiolabeled probe forms covalent adducts with the active-site serine of MGLL, fundamentally changing the binding characteristic to achieve irreversible, high-specificity target engagement that reliably indicates inhibitor efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These probes allow for non-invasive assessment of MGLL enzyme occupancy, facilitating the evaluation of MGLL inhibitors' efficacy and target engagement in the CNS, supporting the development of novel therapeutics for pain, inflammation, and neurodegenerative disorders.
Implementation Method 1
the radiolabeled MGLL occupancy probe forms a covalent adduct with the active-site serine in MGLL
Implementation Method 2
containing a positron emission tomography (PET) tracer radionuclide; wherein the PET tracer radionuclide is 18F, 15O, or 13N
Data Source
AI summary
Provided herein are monoacylglycerol lipase (MGLL) occupancy probes comprising a MGLL inhibitor containing a positron emission tomography (PET) tracer radionuclide. Also provided are methods of assessing MGLL enzyme occupancy of a MGLL inhibitor using the radiolabeled occupancy probes described herein.